Suggestions
Cariad Chester
Cariad Chester is a Managing Partner at TCG Crossover (TCGX), a life sciences-focused investment firm.13 Here's a comprehensive overview of his background and role:
Professional Experience
Cariad Chester joined TCGX in 2021 and was recently promoted to Managing Partner as part of the initiation of TCGX's Fund II.1 Prior to his role at TCGX, he served as a Managing Director at Aquilo Capital, where he led investments in biotechnology companies developing human therapeutics.24
Academic and Research Background
Chester has a strong scientific background. He was previously a research scientist at Stanford University, where he studied tumor-immune system interactions during cancer progression and treatment. He has authored or co-authored over 20 peer-reviewed manuscripts and presented research at conferences in Canada, the US, and China.2
Education
Cariad Chester received his B.A. from Swarthmore College, where he double majored in Neuroscience and Comparative Religious Studies.2
Investment Track Record
Chester has an impressive track record of successful investments in the biotech sector. Some of his notable investments include:
- Icosavax (acquired by AstraZeneca)
- Iveric Bio (acquired by Astellas)
- Gracell Biotechnologies (acquired by AstraZeneca)
- Versanis (acquired by Eli Lilly)
- Akouos (acquired by Eli Lilly)
- VectivBio (acquired by Ironwood)
- Carmot (acquired by Roche)
- Upstream Bio (NASDAQ: UPB)
- Tourmaline Bio (NASDAQ: TRML)
- Structure Therapeutics (NASDAQ: GPCR)2
Current Board Positions
Cariad Chester currently serves on the Board of Directors for several companies, including:
His role at TCGX and his extensive experience in biotechnology investments make Cariad Chester a key figure in the life sciences investment landscape.
